» Articles » PMID: 27001409

Cost-effectiveness of Screening Strategies to Detect Heart Failure in Patients with Type 2 Diabetes

Overview
Publisher Biomed Central
Date 2016 Mar 23
PMID 27001409
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Heart failure (HF), especially with preserved ejection fraction (HFpEF) is common in older patients with type 2 diabetes (T2DM), but often not recognized. Early HF detection in older T2DM patients may be worthwhile because treatment may be initiated in an early stage, with clear beneficial treatment in those with reduced ejection fraction (HFrEF), but without clear prognostic beneficial treatment in those with HFpEF. Because both types of HF may be uncovered in older T2DM, screening may improve health outcomes at acceptable costs. We assessed the cost-effectiveness of five screening strategies in patients with T2DM aged 60 years or over.

Methods: We built a Markov model with a lifetime horizon based on the prognostic results from our screening study of 581 patients with T2DM, extended with evidence from literature. Cost-effectiveness was calculated from a Dutch healthcare perspective as additional costs (Euros) per additional quality-adjusted life-year (QALY) gained. We performed probabilistic sensitivity analysis to assess robustness of these outcomes. Scenario analyses were performed to assess the influence of the availability of effective treatment of heart failure with preserved ejection fraction.

Results: For willingness to pay values in the range of €6050/QALY-€31,000/QALY for men and €6300/QALY-€42,000/QALY for women, screening-based checking the electronic medical record for patient characteristics and medical history plus the assessment of symptoms had the highest probability of being cost-effective. For higher willingness-to-pay values, direct echocardiography was the preferred screening strategy. Cost-effectiveness of all screening strategies improved with the increase in effectiveness of treatment for HFpEF.

Conclusions: Screening for HF in older community-dwelling patients with T2DM is cost-effective at the commonly used willingness-to-pay threshold of €20.000/QALY by checking the electronic medical record for patient characteristics and medical history plus the assessment of symptoms. The simplicity of such a strategy makes it feasible for implementation in existing primary care diabetes management programs.

Citing Articles

Epidemiology of heart failure in diabetes: a disease in disguise.

Hoek A, Canto E, Wenker E, Bindraban N, Handoko M, Elders P Diabetologia. 2024; 67(4):574-601.

PMID: 38334818 PMC: 10904471. DOI: 10.1007/s00125-023-06068-2.


Two-Year Changes in Diabetic Kidney Disease Phenotype and the Risk of Heart Failure: A Nationwide Population-Based Study in Korea.

Lee S, Yoo J, Choi H, Han K, Kim K Diabetes Metab J. 2023; 47(4):523-534.

PMID: 37096376 PMC: 10404526. DOI: 10.4093/dmj.2022.0096.


Medical Costs Associated With Diabetes Complications in Medicare Beneficiaries Aged 65 Years or Older With Type 2 Diabetes.

Wang Y, Zhang P, Shao H, Andes L, Imperatore G Diabetes Care. 2022; 45(11):2570-2576.

PMID: 36102675 PMC: 11388581. DOI: 10.2337/dc21-2151.


Updated Cardiovascular Prevention Guideline of the Brazilian Society of Cardiology - 2019.

Precoma D, Oliveira G, Simao A, Dutra O, Coelho O, Izar M Arq Bras Cardiol. 2019; 113(4):787-891.

PMID: 31691761 PMC: 7020870. DOI: 10.5935/abc.20190204.


Costs of clinical events in type 2 diabetes mellitus patients in the Netherlands: A systematic review.

van Schoonhoven A, Gout-Zwart J, de Vries M, van Asselt A, Dvortsin E, Vemer P PLoS One. 2019; 14(9):e0221856.

PMID: 31490989 PMC: 6730996. DOI: 10.1371/journal.pone.0221856.


References
1.
Kelder J, Cramer M, Wijngaarden J, van Tooren R, Mosterd A, Moons K . The diagnostic value of physical examination and additional testing in primary care patients with suspected heart failure. Circulation. 2011; 124(25):2865-73. DOI: 10.1161/CIRCULATIONAHA.111.019216. View

2.
van Dieren S, Beulens J, van der Schouw Y, Grobbee D, Neal B . The global burden of diabetes and its complications: an emerging pandemic. Eur J Cardiovasc Prev Rehabil. 2010; 17 Suppl 1:S3-8. DOI: 10.1097/01.hjr.0000368191.86614.5a. View

3.
Boonman-de Winter L, Rutten F, Cramer M, Landman M, Liem A, Rutten G . High prevalence of previously unknown heart failure and left ventricular dysfunction in patients with type 2 diabetes. Diabetologia. 2012; 55(8):2154-62. PMC: 3390708. DOI: 10.1007/s00125-012-2579-0. View

4.
McMurray J, Adamopoulos S, Anker S, Auricchio A, Bohm M, Dickstein K . ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the.... Eur J Heart Fail. 2012; 14(8):803-69. DOI: 10.1093/eurjhf/hfs105. View

5.
Chatterjee S, Moeller C, Shah N, Bolorunduro O, Lichstein E, Moskovits N . Eplerenone is not superior to older and less expensive aldosterone antagonists. Am J Med. 2012; 125(8):817-25. DOI: 10.1016/j.amjmed.2011.12.018. View